Short Interest in Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) Expands By 26.8%

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 8,048,300 shares, an increase of 26.8% from the October 31st total of 6,347,300 shares. Based on an average daily volume of 5,400 shares, the short-interest ratio is currently 1,490.4 days.

Sino Biopharmaceutical Stock Performance

SBMFF stock remained flat at $0.42 during mid-day trading on Friday. 100 shares of the company’s stock were exchanged, compared to its average volume of 1,985. Sino Biopharmaceutical has a 12 month low of $0.31 and a 12 month high of $0.47. The company’s fifty day moving average price is $0.45 and its 200 day moving average price is $0.39.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.